SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
ART: NEW DATA AND NEW INSIGHTS
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
10 of
10
|
SWITCH TO BICTEGRAVIR/F/TAF FROM DTG AND ABC/3TC (ABSTRACT
22)
Jean-Michel Molina
Hôpital Saint-Louis, Paris, France
IMPACT OF RALTEGRAVIR INTENSIFICATION OF FIRST-LINE ART ON IRIS IN THE REALITY TRIAL (ABSTRACT
23)
Diana Gibb
MRC Clinical Trials Unit at UCL, London, United Kingdom
HAIR ANTIRETROVIRAL LEVELS STRONGLY PREDICT VIROLOGIC OUTCOMES IN ACTG'S A5257 TRIAL (ABSTRACT
24)
Monica Gandhi
University of California San Francisco, San Francisco, CA, USA
TENOFOVIR DIPHOSPHATE IN DRIED BLOOD SPOTS IS A STRONG PREDICTOR OF VIRAL SUPPRESSION (ABSTRACT
25)
Jose R Castillo-Mancilla
University of Colorado, Denver, Aurora, CO, USA
MULTIPLE DAILY DOSES OF MK-8591 AS LOW AS 0.25 MG ARE EXPECTED TO SUPPRESS HIV (ABSTRACT
26)
Randolph P Matthews
Merck Research Laboratories, North Wales, PA, USA
COMPARATIVE LYMPHOID TISSUE PHARMACOKINETICS (PK) OF INTEGRASE INHIBITORS (INSTI) (ABSTRACT
27)
Courtney V. Fletcher
University of Nebraska Medical Center, Omaha, NE, USA
RIFAMPIN EFFECT ON TENOFOVIR ALAFENAMIDE (TAF) PLASMA/INTRACELLULAR PHARMACOKINETICS (ABSTRACT
28LB)
Maddalena Cerrone
St Stephen's Clinical Research, Chelsea and Westminster Hospital, London, UK, LONDON, United Kingdom
SYSTEMATIC VS TEST-GUIDED TUBERCULOSIS TREATMENT: DATA OF THE STATIS RANDOMIZED TRIAL (ABSTRACT
29LB)
François-Xavier Blanc
l'institut du thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France
RESULTS OF ACTG A5288: A STRATEGY STUDY IN RLS FOR 3RD-LINE ART CANDIDATES (ABSTRACT
30LB)
Beatriz Grinsztejn
Fiocruz, Rio de Janeiro, Brasil, Brazil
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
10 of
10
|
